Capstone Therapeutics Corp.
- Jurisdiction
United States - LEI
549300ZH6K9NJJQJ7Q84 - ISIN
US14068E2081 (CAPS )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
6
/ 7
Profile
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. Read full profile
Fundamentals
- Net revenue
€37.00M - Gross margin
21.9% - EBIT
-€1.38M - EBIT margin
-3.7% - Net income
-€3.58M - Net margin
-9.7%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions